Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Return on equity
Solventum Corporation's return on equity over the twelve months to 30 June 2026 was 34.0%, down 4.9 percentage points from fiscal 2025 (38.9%). That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 38.9% | 32.31 |
| FY2024 | 6.55% | 6.55 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | — |
Return on equity against peers
| Company | Return on equity |
|---|---|
| SOLV Solventum Corporation | 34.0% |
| WST West Pharmaceutical Services, Inc. compare | 19.1% |
| ATR AptarGroup, Inc. compare | 13.5% |
| ALGN Align Technology, Inc. compare | 10.2% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| ALC Alcon compare | 2.94% |
| RGEN Repligen Corporation compare | 1.99% |
| AVTR Avantor, Inc. compare | −9.70% |
| BAX Baxter International Inc. compare | −15.8% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement